Widely used:Recently Viewed
Clear All
$3,034 Mln
--
77.12
--
0
-248.14 %
--
0 %
0.64
-4345544
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Rhythm Pharmaceuticals (RYTM)
| 7.96 | 8.01 | 21.61 | 130.09 | 55.93 | 18.89 | -- |
|
BSE Sensex*
| 12.20 | -0.16 | 1.32 | 22.81 | 11.05 | 16.56 | 11.80 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Rhythm Pharmaceuticals (RYTM)
| 57.86 | 191.78 | -66.43 | 29.49 | -14.58 | -7.46 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
loading... |
|||
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Our rating system has guided millions of investors in the past 20 years.
$3,034.07 Mln
$101.78 Mln
$0.00 Mln
$319.13 Mln
$252.64 Mln
High
$20.97 - 55.64
61,133,800
NASDAQ: RYTM
Boston, MA
https://rhythmtx.com
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of... pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Read more
The total asset value of Rhythm Pharmaceuticals Inc (RYTM) stood at $ 437 Mln as on 30-Jun-24
The share price of Rhythm Pharmaceuticals Inc (RYTM) is $49.63 (NASDAQ) as of 04-Oct-2024 16:00 EDT. Rhythm Pharmaceuticals Inc (RYTM) has given a return of 55.93% in the last 3 years.
Rhythm Pharmaceuticals Inc (RYTM) has a market capitalisation of $ 3,034 Mln as on 04-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Rhythm Pharmaceuticals Inc (RYTM) is 77.12 times as on 04-Oct-2024, a 2372% premium to its peers’ median range of 3.12 times.
Since, TTM earnings of Rhythm Pharmaceuticals Inc (RYTM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Rhythm Pharmaceuticals Inc (RYTM) and enter the required number of quantities and click on buy to purchase the shares of Rhythm Pharmaceuticals Inc (RYTM).
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
The CEO & director of Dr. David P. Meeker M.D.. is Rhythm Pharmaceuticals Inc (RYTM), and CFO & Sr. VP is Dr. David P. Meeker M.D..
There is no promoter pledging in Rhythm Pharmaceuticals Inc (RYTM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,034
|
|
|
1,002
|
|
|
998
|
|
|
875
|
| Rhythm Pharmaceuticals Inc. (RYTM) | Ratios |
|---|---|
|
Return on equity(%)
|
-248.14
|
|
Operating margin(%)
|
-253.91
|
|
Net Margin(%)
|
-254.88
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Rhythm Pharmaceuticals Inc (RYTM) was $0 Mln.
$1.05
